logo
  

Pfizer - BioNTech COVID-19 Vaccine Recommended For Full Approval In EU

Pfizer Inc. (PFE) and BioNTech SE (BNTX) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency (EMA) has recommended converting the conditional Marketing Authorization (cMA) for their COVID-19 Vaccine COMIRNATY to Full Marketing Authorization for all authorized indications and formulations.

The recommendation applies to all indications and formulations in the European Union, including COMIRNATY Original/Omicron BA.4-5 and COMIRNATY Original/Omicron BA.1 bivalent vaccines.

The European Commission will review the CHMP recommendation and is soon expected to make a final decision.

In a separate action, the CHMP also recommended approval for COMIRNATY as a 10-microgram booster (third) dose given at least six months after completion of a primary series for children 5 through 11 years of age. COMIRNATY 10- microgram was authorized in the EU in November 2021 as a two-dose primary series for children 5 through 11 years of age.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT